Skip to main content
Premium Trial:

Request an Annual Quote

Gene Logic Posts Revenue Gains, Narrowed Loss in Q3

NEW YORK, Oct. 28 - Gene Logic today said that an increase in GeneExpress subscribers helped boost third-quarter revenue by 23 percent. In addition, despite a boost in R&D spending and overall expenses, net loss in the quarter narrowed.


For the three-month period ended Sept. 30, Gene Logic reported $14.2 million in total receipts, up from $11.5 for the same quarter one year ago.


R&D spending in the quarter grew to $17.3 million from $14.5 million in the third quarter last year, and SG&A fell to $4.3 million in the current quarter from $4.7 million year over year, the company said.


Net loss narrowed during the third quarter to $7 million, or $.26 per share, from $7.2 million, or $.27 per share, year over year.


Gene Logic said it had roughly $171.9 million in cash and cash equivalents as of Sept. 30.


Click here for more information.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.